心血管疾病是當今世界威脅人類健康的頭號殺手，心力衰竭是眾多心血管疾病的終點。隨著人口老齡化的發(fā)展和新的心力衰竭亞型的出現(xiàn)，傳統(tǒng)抗心力衰竭藥物的療效難以令人滿意。近年來，新型降糖藥鈉–葡萄糖協(xié)同轉(zhuǎn)運蛋白2（SGLT2）抑制劑在心血管結(jié)局研究中表現(xiàn)出了良好的效果，展現(xiàn)了此類藥物巨大的研究價值。從臨床試驗結(jié)果、心臟功能改善和作用機制分析3個方面綜述SGLT2抑制劑治療心力衰竭的研究進展。

Cardiovascular disease is the number one killer threatening human health in the world today, and heart failure is the end point of many cardiovascular diseases. With the development of the aging population and the emergence of new heart failure subtypes, the efficacy of traditional anti-heart failure drugs is not satisfactory. In recent years, new-type hypoglycemic drugs sodium glucose transporter 2 (SGLT2) inhibitors have shown good effects in cardiovascular outcome studies, demonstrating the tremendous research value of such drugs. This article reviews the research progress of SGLT2 inhibitors on heart failure from three aspects:clinical trial results, cardiac function improvement and potential mechanism analysis.

R972

國家科技重大專項重大新藥創(chuàng)制項目（2019ZX09201005-007）